A fast growing genetically engineered salmon is a good bet for approval by the Food and Drug Administration. It would be the first genetically modified animal sold as food. Dubbed “Frankenfish” by opponents, the new version of Atlantic salmon was developed by AquaBounty Technologies. It grows almost twice as fast as farm-raised salmon, thanks to one growth hormone gene from a chinook salmon and another from an eel, the ocean pout. The application has been pending before the agency for well over 10 years.
A congressional effort to ban the fish will fail, although it’s a fair bet that lawmakers will give the FDA the authority to require a label identifying the produce as genetically modified. “Approval of genetically modified salmon, the first such hybrid to be considered for human consumption, is unprecedented, risky and a threat to the survival of wild species,” says Sen. Mark Begich, D-Alaska, whose state has a thriving salmon industry.
Also likely to be on the table: Broadening the mission of regulators to ensure they consider environmental risks before granting future approvals -- not just whether the food is safe and whether animals are harmed by the genetic manipulation.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
A push to add greater public input to the approval process is also a good bet. The current procedure is similar to that for new drugs, with limited public participation. “The current process is confidential. It’s not transparent or participatory,” says Gregory Jaffe of the Center for Science in the Public Interest.
Next up: The Enviropig -- a porker genetically altered to make the manure it produces less polluting, with phosphorus levels 30% to 65% lower than normal. It’s being developed by scientists at the University of Guelph in Canada. Also in the works from Hematech Inc. are cattle that are not susceptible to mad cow disease. The animals lack a protein that mutates, so they don’t get the disease and can’t pass it on.
-
The Robots Are Coming... But Not For a WhileThe Kiplinger Letter There’s excitement in the tech sector over the potential of humanoid robots, but widespread adoption is likely to be years away.
-
Farmers Face Another Tough Year As Costs Continue to Climb: The Kiplinger LetterThe Kiplinger Letter Farm income is expected to decline for a second year, while costs continue to up-end farm profitability.
-
H-1B Work Visa Rules Get a RevampThe Kiplinger Letter H-1B visas allow employers to hire high-skilled foreign workers. Regulators have finalized new rules for this visa program following last fall's proposal.
-
Woes Continue for Banking Sector: The Kiplinger LetterThe Kiplinger Letter Regional bank stocks were hammered recently after news of New York Community Bank’s big fourth-quarter loss.
-
Are College Athletes Employees of Their Schools?: The Kiplinger LetterThe Kiplinger Letter A recent ruling has ramifications for labor relations and the unionization of student athletes.
-
Salton Sea Clean Energy and Lithium Project Gets Approval: The Kiplinger LetterThe Kiplinger Letter California's Salton Sea is due to see the construction of a new lithium extraction and geothermal clean energy power plant.
-
More Woes for Anheuser-Busch as a Strike Looms: The Kiplinger LetterThe Kiplinger Letter Drinkers of Anheuser-Busch beers may want to stock up soon. A looming strike threatens to shutter its U.S. breweries later this month.
-
The Auto Industry Outlook for 2024The Kiplinger Letter Here's what to expect in the auto industry this year. If you’re in the market for a car it won’t be quite as daunting as it was during the pandemic and after.
